Abstract
5596 Background: The prognosis for advanced CC and EC pts is poor, with relapse to approved chemotherapies inevitable. In view of the high rate of putative driver mutations, novel MTAs in phase I t...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
